FOLD
Price
$14.25
Change
+$0.04 (+0.28%)
Updated
Dec 24 closing price
Capitalization
4.41B
55 days until earnings call
Intraday BUY SELL Signals
RARE
Price
$34.58
Change
+$0.45 (+1.32%)
Updated
Dec 24 closing price
Capitalization
3.34B
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FOLD vs RARE

Header iconFOLD vs RARE Comparison
Open Charts FOLD vs RAREBanner chart's image
Amicus Therapeutics
Price$14.25
Change+$0.04 (+0.28%)
Volume$5.94M
Capitalization4.41B
Ultragenyx Pharmaceutical
Price$34.58
Change+$0.45 (+1.32%)
Volume$721.61K
Capitalization3.34B
FOLD vs RARE Comparison Chart in %
View a ticker or compare two or three
VS
FOLD vs. RARE commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Buy and RARE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (FOLD: $14.25 vs. RARE: $34.58)
Brand notoriety: FOLD and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 59% vs. RARE: 51%
Market capitalization -- FOLD: $4.41B vs. RARE: $3.34B
FOLD [@Biotechnology] is valued at $4.41B. RARE’s [@Biotechnology] market capitalization is $3.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, FOLD is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • FOLD’s TA Score: 4 bullish, 4 bearish.
  • RARE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RARE is a better buy in the short-term than FOLD.

Price Growth

FOLD (@Biotechnology) experienced а +29.55% price change this week, while RARE (@Biotechnology) price change was +4.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

FOLD is expected to report earnings on Feb 19, 2026.

RARE is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($4.41B) has a higher market cap than RARE($3.34B). FOLD YTD gains are higher at: 51.274 vs. RARE (-17.804). FOLD has higher annual earnings (EBITDA): 59.3M vs. RARE (-483.37M). RARE has more cash in the bank: 425M vs. FOLD (264M). RARE has less debt than FOLD: RARE (33.8M) vs FOLD (443M). RARE has higher revenues than FOLD: RARE (631M) vs FOLD (599M).
FOLDRAREFOLD / RARE
Capitalization4.41B3.34B132%
EBITDA59.3M-483.37M-12%
Gain YTD51.274-17.804-288%
P/E RatioN/AN/A-
Revenue599M631M95%
Total Cash264M425M62%
Total Debt443M33.8M1,311%
FUNDAMENTALS RATINGS
FOLD vs RARE: Fundamental Ratings
FOLD
RARE
OUTLOOK RATING
1..100
3516
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
97
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
3556
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
509

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (61) in the Biotechnology industry is somewhat better than the same rating for RARE (97). This means that FOLD’s stock grew somewhat faster than RARE’s over the last 12 months.

FOLD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's SMR Rating (93) in the Biotechnology industry is in the same range as RARE (100). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's Price Growth Rating (35) in the Biotechnology industry is in the same range as RARE (56). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDRARE
RSI
ODDS (%)
Bearish Trend 2 days ago
63%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 17 days ago
75%
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
FOLD
Daily Signal:
Gain/Loss:
RARE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRDPX91.420.39
+0.43%
Franklin Rising Dividends A
MVSSX33.490.09
+0.27%
Victory Integrity Small-Cap Value R6
MIVIX30.210.05
+0.17%
Madison Large Cap I
NSDVX21.50N/A
N/A
North Star Dividend I
KGGAX16.68-0.01
-0.06%
Kopernik Global All-Cap A

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with BMRN. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
+0.28%
BMRN - FOLD
59%
Loosely correlated
-1.60%
XNCR - FOLD
44%
Loosely correlated
-0.13%
RARE - FOLD
44%
Loosely correlated
+1.32%
VCYT - FOLD
43%
Loosely correlated
-0.35%
KURA - FOLD
43%
Loosely correlated
+2.50%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+1.32%
MREO - RARE
70%
Closely correlated
+0.44%
XNCR - RARE
48%
Loosely correlated
-0.13%
RGNX - RARE
47%
Loosely correlated
+0.77%
DNLI - RARE
47%
Loosely correlated
+1.07%
VCYT - RARE
46%
Loosely correlated
-0.35%
More